Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Fundamental Analysis

NYSE:DNA - New York Stock Exchange, Inc. - US37611X2099 - Common Stock - Currency: USD

10.82  -0.61 (-5.34%)

After market: 10.93 +0.11 (+1.02%)

Fundamental Rating

4

Taking everything into account, DNA scores 4 out of 10 in our fundamental rating. DNA was compared to 85 industry peers in the Chemicals industry. No worries on liquidiy or solvency for DNA as it has an excellent financial health rating, but there are worries on the profitability. DNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNA had negative earnings in the past year.
In the past year DNA has reported a negative cash flow from operations.
DNA had negative earnings in each of the past 5 years.
In the past 5 years DNA always reported negative operating cash flow.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -500M -1B -1.5B -2B

1.2 Ratios

DNA has a Return On Assets of -43.97%. This is amonst the worse of the industry: DNA underperforms 92.77% of its industry peers.
With a Return On Equity value of -81.61%, DNA is not doing good in the industry: 90.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -43.97%
ROE -81.61%
ROIC N/A
ROA(3y)-74.96%
ROA(5y)-52.15%
ROE(3y)-108.06%
ROE(5y)-75.16%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of DNA (80.94%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of DNA has remained more or less at the same level.
DNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5YN/A
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNA has less shares outstanding than it did 1 year ago.
There is no outstanding debt for DNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

DNA has an Altman-Z score of -5.22. This is a bad value and indicates that DNA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.22, DNA is not doing good in the industry: 84.34% of the companies in the same industry are doing better.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.22
ROIC/WACCN/A
WACC9.14%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 5.79 indicates that DNA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 5.79, DNA belongs to the best of the industry, outperforming 95.18% of the companies in the same industry.
DNA has a Quick Ratio of 5.79. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.79, DNA belongs to the top of the industry, outperforming 95.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.79
Quick Ratio 5.79
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.00% over the past year.
Looking at the last year, DNA shows a very negative growth in Revenue. The Revenue has decreased by -30.81% in the last year.
DNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.56% yearly.
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.31%
Revenue 1Y (TTM)-30.81%
Revenue growth 3Y48.56%
Revenue growth 5YN/A
Sales Q2Q%60.65%

3.2 Future

The Earnings Per Share is expected to grow by 14.81% on average over the next years. This is quite good.
The Revenue is expected to grow by 34.19% on average over the next years. This is a very strong growth
EPS Next Y46.71%
EPS Next 2Y26.67%
EPS Next 3Y19.03%
EPS Next 5Y14.81%
Revenue Next Year-11.97%
Revenue Next 2Y-11.25%
Revenue Next 3Y-0.74%
Revenue Next 5Y34.19%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as DNA's earnings are expected to grow with 19.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.67%
EPS Next 3Y19.03%

More info and screens

0

5. Dividend

5.1 Amount

DNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (2/21/2025, 8:14:12 PM)

After market: 10.93 +0.11 (+1.02%)

10.82

-0.61 (-5.34%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners63.43%
Inst Owner Change-42.88%
Ins Owners6.44%
Ins Owner Change0.11%
Market Cap589.47M
Analysts43.08
Price Target9.59 (-11.37%)
Short Float %19.93%
Short Ratio5.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.51%
Min EPS beat(2)11.15%
Max EPS beat(2)65.88%
EPS beat(4)3
Avg EPS beat(4)17.33%
Min EPS beat(4)-12.66%
Max EPS beat(4)65.88%
EPS beat(8)4
Avg EPS beat(8)1.88%
EPS beat(12)4
Avg EPS beat(12)-321.5%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)62.46%
Min Revenue beat(2)29.01%
Max Revenue beat(2)95.92%
Revenue beat(4)2
Avg Revenue beat(4)21.87%
Min Revenue beat(4)-19.04%
Max Revenue beat(4)95.92%
Revenue beat(8)6
Avg Revenue beat(8)16.79%
Revenue beat(12)10
Avg Revenue beat(12)28.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.63%
PT rev (3m)-36.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3060.71%
EPS NY rev (1m)1.88%
EPS NY rev (3m)21.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)22.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.7
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-11.34
EYN/A
EPS(NY)-7.44
Fwd EYN/A
FCF(TTM)-7.11
FCFYN/A
OCF(TTM)-6.15
OCFYN/A
SpS4
BVpS14.65
TBVpS13.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.97%
ROE -81.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.94%
FCFM N/A
ROA(3y)-74.96%
ROA(5y)-52.15%
ROE(3y)-108.06%
ROE(5y)-75.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.82%
Cap/Sales 23.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.79
Quick Ratio 5.79
Altman-Z -5.22
F-Score3
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)125.02%
Cap/Depr(5y)199.75%
Cap/Sales(3y)15.06%
Cap/Sales(5y)32.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.31%
EPS Next Y46.71%
EPS Next 2Y26.67%
EPS Next 3Y19.03%
EPS Next 5Y14.81%
Revenue 1Y (TTM)-30.81%
Revenue growth 3Y48.56%
Revenue growth 5YN/A
Sales Q2Q%60.65%
Revenue Next Year-11.97%
Revenue Next 2Y-11.25%
Revenue Next 3Y-0.74%
Revenue Next 5Y34.19%
EBIT growth 1Y41.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.7%
EBIT Next 3Y24.39%
EBIT Next 5Y27.48%
FCF growth 1Y-12.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.95%
OCF growth 3YN/A
OCF growth 5YN/A